Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction

Diabetes, Obesity and Metabolism

Volumn 20, Issue 10, 2018, Pages 2399-2407

  Lachaux, Marianne ^a   Barrera Chimal, Jonatan ^b   Nicol, Lionel ^a   Rémy Jouet, Isabelle ^a   Renet, Sylvanie ^a   Dumesnil, Anais ^a   Wecker, Didier ^c   Richard, Vincent ^a   Kolkhof, Peter ^d   Jaisser, Frederic ^b   Ouvrard Pascaud, Antoine ^a   Mulder, Paul ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b INSERM   (France)

^c BRUKER BIOSPIN GMBH   (Germany)

^d BAYER AG   (Germany)

Author keywords

animal pharmacology; cardiovascular disease; diabetes complications; drug development; experimental pharmacology; type 2 diabetes

Indexed keywords

FINERENONE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART DISEASE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART WEIGHT; KIDNEY DISEASE; LONG TERM CARE; MALE; METABOLIC SYNDROME X; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEINURIA; RAT; SHORT COURSE THERAPY; SYSTOLIC BLOOD PRESSURE; TISSUE PERFUSION; TREATMENT DURATION; ANIMAL; CARDIOVASCULAR DISEASE; COMPLICATION; DRUG ADMINISTRATION; HEART RATE; HEMODYNAMICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR; ZUCKER RAT;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; HEART RATE; HEMODYNAMICS; KIDNEY DISEASES; MALE; METABOLIC SYNDROME; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; NITRIC OXIDE; OXIDATIVE STRESS; RATS; RATS, ZUCKER; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 85053080463     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13393     Document Type: Article

References (62)

1. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the national health and nutrition examination survey ii mortality study. Atherosclerosis. 2004;173:309-314
2. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-2449
3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689
4. Celentano A, Palmieri V, Panico S, et al. Individuals' cardiovascular risk profile projected by family doctors and individuals' knowledge of cardiovascular risk factors: a challenge for primary prevention. The cardiovascular risk prevention project "help your heart stay young". Ital Heart J. 2005;6:557-564
5. Knudson JD, Dincer UD, Bratz IN, Sturek M, Dick GM, Tune JD. Mechanisms of coronary dysfunction in obesity and insulin resistance. Microcirculation. 2007;14:317-338
6. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-1904
7. Sola S, Mir MQ, Cheema FA, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the irbesartan and lipoic acid in endothelial dysfunction (island) study. Circulation. 2005;111:343-348
8. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350:266-272
9. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007;5:e012
10. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257-263
11. Brilla CG. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res. 2000;47:1-3
12. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709-717
13. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post-AMI heart failure efficacy and survival study. Cardiovasc Drugs Ther. 2001;15:79-87
14. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321
15. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21
16. Barfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385-1403
17. Amazit L, Le Billan F, Kolkhof P, et al. Finerenone Impedes Aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290:21876-21889
18. Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69-78
19. Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity. Hypertension. 2018;71:599-608
20. Fang Y, Nicol L, Harouki N, et al. Improvement of left ventricular diastolic function induced by beta-blockade. J Mol Cell Cardiol. 2011;51:168-176
21. Turkstra E, Braam B, Koomans HA. Impaired renal blood flow autoregulation in two-kidney, one-clip hypertensive rats is caused by enhanced activity of nitric oxide. J Am Soc Nephrol. 2000;11:847-855
22. Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994;89:345-354
23. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long- term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976-1982
24. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in m-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083
25. Waller C, Hiller KH, Voll S, Haase A, Ertl G, Bauer WR. Myocardial perfusion imaging using a non-contrast agent MR imaging technique. Int J Cardiovasc Imaging. 2001;17:123-132
26. Kober F, Iltis I, Cozzone PJ, Bernard M. Myocardial blood flow mapping in mice using high-resolution spin labeling magnetic resonance imaging: influence of ketamine/xylazine and isoflurane anesthesia. Magn Reson Med. 2005;53:601-606
27. Mulder P, Mellin V, Favre J, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008;29:2171-2179
28. Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J. 2005;26:1544-1550
29. MacArthur PH, Shiva S, Gladwin MT. Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:93-105
30. Henry RJ, Segalove M, Sobel C. Turbidimetric determination of proteins with sulfosalicylic and trichloracetic acids. Proc Soc Exp Biol Med. 1956;92:748-751
31. Gueret A, Harouki N, Favre J, et al. Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension. 2016;67:717-723
32. Merabet N, Fang Y, Nicol L, et al. Selective heart rate reduction improves metabolic syndrome-related left ventricular diastolic dysfunction. J Cardiovasc Pharmacol. 2015;66:399-408
33. Lauer T, Preik M, Rassaf T, et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A. 2001;98:12814-12819
34. Toblli JE, Cao G, Giani JF, Angerosa M, Dominici FP, Gonzalez-Cadavid NF. Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press Res. 2012;34:20-33
35. Palomo I, Contreras A, Alarcon LM, et al. Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. Nitric Oxide. 2011;24:224-228
36. Paulus WJ, Shah AM. No and cardiac diastolic function. Cardiovasc Res. 1999;43:595-606
37. van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117:43-51
38. Bender SB, DeMarco VG, Padilla J, et al. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension. 2015;65:1082-1088
39. Gillebert TC, De Hert SG, Andries LJ, Jageneau AH, Brutsaert DL. Intracavitary ultrasound impairs left ventricular performance: presumed role of endocardial endothelium. Am J Physiol. 1992;263:H857-H865
40. van Heerebeek L, Somsen A, Paulus WJ. The failing diabetic heart: focus on diastolic left ventricular dysfunction. Curr Diab Rep. 2009;9:79-86
41. El-Omar MM, Lord R, Draper NJ, Shah AM. Role of nitric oxide in posthypoxic contractile dysfunction of diabetic cardiomyopathy. Eur J Heart Fail. 2003;5:229-239
42. Silberman GA, Fan TH, Liu H, et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation. 2010;121:519-528
43. Matter CM, Mandinov L, Kaufmann PA, Vassalli G, Jiang Z, Hess OM. Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. Circulation. 1999;99:2396-2401
44. Fraccarollo D, Widder JD, Galuppo P, et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation. 2008;118:818-827
45. Serpillon S, Floyd BC, Gupte RS, et al. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol. 2009;297:H153-H162
46. Rosen P, Osmers A. Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose. Horm Metab Res. 2006;38:575-586
47. Zhou X, Ma L, Habibi J, et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension. 2010;55:880-888
48. Kapadia SR. Cytokines and heart failure. Cardiol Rev. 1999;7:196-206
49. Luyt CE, Lepailleur-Enouf D, Gaultier CJ, Valdenaire O, Steg G, Michel JB. Involvement of the endothelin system in experimental critical hind limb ischemia. Mol Med. 2000;6:947-956
50. Jain M, Brenner DA, Cui L, et al. Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ Res. 2003;93:e9-e16
51. Kuster GM, Lancel S, Zhang J, et al. Redox-mediated reciprocal regulation of SERCA and Na+-Ca2+ exchanger contributes to sarcoplasmic reticulum Ca2+ depletion in cardiac myocytes. Free Radic Biol Med. 2010;48:1182-1187
52. Maczewski M, Mackiewicz U. Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. Cardiovasc Res. 2008;79:42-51
53. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 2001;280:C53-C60
54. Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol Cell Biochem. 2008;317:43-50
55. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116-2123
56. Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res. 2007;101:335-347
57. Chess DJ, Lei B, Hoit BD, Azimzadeh AM, Stanley WC. Deleterious effects of sugar and protective effects of starch on cardiac remodeling, contractile dysfunction, and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol. 2007;293:H1853-H1860
58. Yamaji M, Tsutamoto T, Kawahara C, et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure. Am Heart J. 2010;160:915-921
59. Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33:2782-2795
60. Frisbee SJ, Singh SS, Jackson DN, et al. Beneficial pleiotropic antidepressive effects of cardiovascular disease risk factor interventions in the metabolic syndrome. J Am Heart Assoc. 2018;7(7):e008185
61. Brooks SD, Hileman SM, Chantler PD, et al. Protection from vascular dysfunction in female rats with chronic stress and depressive symptoms. Am J Physiol Heart Circ Physiol. 2018;314:H1070-H1084
62. Brooks SD, Hileman SM, Chantler PD, et al. Protection from chronic stress- and depressive symptom-induced vascular endothelial dysfunction in female rats is abolished by preexisting metabolic disease. Am J Physiol Heart Circ Physiol. 2018;314:H1085-H1097